BeyondSpring’s Phase 3 NSCLC Trial Delivers HR 0.72 OS Benefit, DUBLIN-4 Planned
BeyondSpring’s Phase 3 DUBLIN-3 combining plinabulin with docetaxel in EGFR wild-type NSCLC achieved OS hazard ratio 0.72, a 2.5-month OS gain and reduced grade 4 neutropenia to 5%, prompting DUBLIN-4 Phase 3 (NCT07361484). The company completed $30 million financing and launched Phase 1a of ST-01156 after IND clearance in US and China.
1. Clinical Trial Results
BeyondSpring reported that its DUBLIN-3 Phase 3 study of plinabulin plus docetaxel in EGFR wild-type NSCLC (n=559) achieved an overall survival hazard ratio of 0.72 (p=0.0078), a median OS improvement of 2.5 months, doubled 2- and 3-year survival rates, and cut grade 4 neutropenia from over 30% to 5%. More than 700 patients have now been treated with plinabulin across clinical trials, supporting its safety and tolerability profile.
2. Planned Confirmatory Study
Based on DUBLIN-3 results and discussions with the US FDA, BeyondSpring will initiate DUBLIN-4, a global Phase 3 confirmatory trial (NCT07361484) enrolling EGFR wild-type non-squamous NSCLC patients who progressed on prior PD-1/L1 inhibitors, with overall survival as the primary endpoint.
3. SEED Therapeutics Update
SEED Therapeutics, an equity-controlled affiliate, dosed its first patient in January 2026 for ST-01156, a novel oral RBM39 degrader, following IND clearance in both the US and China. This Phase 1a initiation marks SEED’s entry into clinical development and expands BeyondSpring’s pipeline footprint.
4. Financial and Leadership Updates
In March 2026, BeyondSpring closed a $30 million Series A-3 financing round and appointed Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer. These moves bolster the company’s balance sheet and leadership as it advances plinabulin’s DUBLIN-4 trial and supports SEED’s ST-01156 program.